公开(公告)号：US20170355712A1

公开(公告)日：2017-12-14

申请号：US15601888

申请日：2017-05-22

Applicant: Epizyme, Inc.

Inventor： John Emmerson Campbell ,  Kenneth William Duncan ,  Megan Alene Foley ,  Darren Martin Harvey ,  Kevin Wayne Kuntz ,  James Edward John Mills ,  Michael John Munchhof

IPC: C07D498/04 ,  C07D405/14 ,  C07D405/12 ,  C07D215/38 ,  C07D487/04 ,  C07D491/044 ,  C07D401/14 ,  C07D401/12 ,  C07D213/74 ,  C07D473/32 ,  C07D239/49 ,  C07D403/14 ,  C07D239/48 ,  C07D413/12 ,  C07D471/04 ,  C07D413/14 ,  C07D403/12 ,  C07D409/14

CPC classification number: C07D498/04 ,  C07D213/74 ,  C07D215/38 ,  C07D231/38 ,  C07D239/48 ,  C07D239/49 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D473/32 ,  C07D487/04 ,  C07D491/044

Abstract: The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.